About this Tool

The Neulasta (pegfilgrastim) Dosing Calculator is a clinical support resource for healthcare professionals. It determines the appropriate dose and administration schedule for pegfilgrastim products based on patient characteristics and chemotherapy timing. This information is intended to supplement, not replace, clinical judgment and the official prescribing information.

Outputs Explained

After entering the required patient data, the calculator provides the following key outputs:

• Recommended Dose: The precise dose in milligrams (mg) and the corresponding volume in milliliters (mL).
• Patient Summary: A confirmation of the patient type (Adult or Pediatric) and weight used for the calculation.
• Administration Schedule: For prefilled syringes, it provides a specific date range (24 to 96 hours) for administration after chemotherapy. For the Onpro on-body injector, it confirms the timing of the automated delivery (~27 hours post-application).
• Clinical Warnings: Important safety information and clinical considerations relevant to the administration of pegfilgrastim.

How to Use the Calculator

To ensure an accurate calculation, follow these steps:

1. Select Patient Type: Choose either 'Adult' or 'Pediatric'. If 'Pediatric' is selected, an age input field will appear.
2. Enter Patient Weight: Input the patient's weight and select the appropriate unit (kg or lbs).
3. Select Indication: Choose the reason for administration (e.g., Prophylaxis of Febrile Neutropenia).
4. Enter Chemotherapy Date: Use the calendar to select the date the patient received myelosuppressive chemotherapy. This is crucial for calculating the correct administration window.
5. Choose a Product: Select the specific pegfilgrastim product being used, including Neulasta, Neulasta Onpro, or available biosimilars.

Dosing Overview

Pegfilgrastim dosing is based on patient age and weight, as outlined in the prescribing information.

• Adult Patients: A single fixed dose of 6 mg is recommended once per chemotherapy cycle.
• Pediatric Patients: Dosing is weight-based to ensure appropriate exposure.
  • Weight less than 10 kg: 0.1 mg/kg
  • Weight 10 to 20 kg: 1.5 mg
  • Weight 21 to 30 kg: 2.5 mg
  • Weight 31 to 44 kg: 4 mg
  • Weight 45 kg or more: 6 mg (adult dose)

Switching Between Products

Healthcare providers may switch between Neulasta and its biosimilars (e.g., Fulphila, Udenyca, Ziextenzo). Biosimilars have been approved by regulatory bodies like the FDA as having no clinically meaningful differences from the reference product. Always follow local and institutional guidelines for formulary and interchangeability when making a switch.

Missed Dose

If a dose of pegfilgrastim from a prefilled syringe is missed, it should be administered as soon as possible. The timing of subsequent chemotherapy may need to be adjusted to maintain the required interval between pegfilgrastim administration and the next chemotherapy dose. Consult the prescribing information and institutional protocols for specific guidance.

Safety Alerts

Frequently Asked Questions (FAQ)

1. Why is the chemotherapy date a required input?
The date is essential to calculate the safe and effective administration window, which is between 24 and 96 hours after chemotherapy completion for prefilled syringes.

2. Can this calculator be used for pegfilgrastim biosimilars?
Yes, the calculator includes several FDA-approved biosimilars in its product selection dropdown, as they share the same dosing and administration principles as Neulasta.

3. What is the main difference between the Neulasta syringe and the Onpro device?
The prefilled syringe requires a manual injection by a healthcare provider (or patient/caregiver) during a specific window. The Onpro is an on-body device applied on the day of chemo that automatically delivers the dose approximately 27 hours later, eliminating the need for a return visit.

4. Is the 6 mg dose for adults adjusted for very high or low body weight?
No, the approved adult dose is a fixed 6 mg regardless of body weight.

5. How does the calculator determine the pediatric dose?
It uses the tiered, weight-based dosing schedule recommended in the official prescribing information, which transitions to the fixed adult dose for children weighing 45 kg or more.

6. What should be done if an Onpro device fails or falls off?
The patient should contact their healthcare provider immediately. A replacement dose via a prefilled syringe may be necessary if the full dose was not delivered.

7. What is H-ARS?
H-ARS stands for Hematopoietic Subsyndrome of Acute Radiation Syndrome. Pegfilgrastim is indicated to increase survival in patients acutely exposed to myelosuppressive doses of radiation.

8. Can I give a second dose of pegfilgrastim in the same chemotherapy cycle?
Pegfilgrastim is indicated for administration once per chemotherapy cycle. Additional doses are not recommended per the standard schedule.

References